Pramlintide – Purity ?99.94% | CAS No. 151126-32-8 | GMP Manufacturer

Pramlintide – Purity ?99.94% | CAS No. 151126-32-8 | GMP Manufacturer

$2.00

Pramlintide is a stable human amylin analog used adjunctively with insulin to reduce post-meal glucose excursions by slowing gastric emptying, lowering glucagon, and increasing satiety. Purity ?99.94%, produced under GMP conditions. Laboratory research only.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare
Category:

Description

Pramlintide is a synthetic polypeptide analog of human amylin, engineered with three proline substitutions to reduce amyloid formation and improve stability. Co-secreted with insulin from pancreatic ?-cells, amylin complements insulin’s glucose-regulating actions. Pramlintide slows gastric emptying, suppresses postprandial glucagon secretion, and promotes a feeling of fullness—collectively helping to moderate post-meal blood glucose spikes. Clinically approved as an adjunct to mealtime insulin for both type 1 and type 2 diabetes, pramlintide effectively reduces HbA1c, body weight, and insulin dosage. With ?99.94% purity and manufactured to GMP standards, this peptide is ideal for metabolic and endocrinology research focusing on satiety, glucose dynamics, and hormone regulation.


Product Specifications

ParameterDetails
Product NamePramlintide
CAS Number151126-32-8
Purity?99.94% (HPLC)
StructureHuman amylin analog with proline substitutions
FunctionAmylin receptor agonist (modulates glucose regulation postprandially)
Therapeutic UsageAdjunct to insulin therapy in diabetes
AppearanceWhite to off-white lyophilized powder
FormTFA salt
SolubilitySoluble in aqueous solutions; standard peptide handling protocols apply
Storage–20 °C, protected from light and moisture
GMP ComplianceYes – manufactured in GMP-certified facility

Mechanism of Action & Research Applications

Pramlintide acts through multiple mechanisms to support metabolic balance:

  • Slows gastric emptying, delaying nutrient uptake and reducing the rate of glucose absorption

  • Suppresses inappropriate post-meal glucagon secretion, lowering hepatic glucose output

  • Promotes satiety, helping to reduce caloric intake and facilitating weight control

These combined effects not only improve postprandial glycemic control but also aid in managing body weight via appetite regulation. Pramlintide serves as an excellent research model for exploring satiety signaling, incretin-like effects, insulin/amylin synergy, and metabolic control dynamics.


Side Effects (For Research Context Only)

In clinical settings, common adverse effects include nausea, vomiting, anorexia, headache, dizziness, and injection site discomfort. Severe hypoglycemia may occur if mealtime insulin is not adjusted appropriately—usually mitigated by reducing insulin doses upon pramlintide initiation.
For experimental protocols, careful titration and glucose monitoring are essential to preserve safety and data integrity.


Logistics Transportation

All shipments come with full transport insurance and expedited handling. In the rare event of loss, damage, or detention, 100% compensation is guaranteed—ensuring secure and reliable delivery.


Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for clinical, therapeutic, veterinary, or diagnostic applications.

Additional information

Weight0.8 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “Pramlintide – Purity ?99.94% | CAS No. 151126-32-8 | GMP Manufacturer”

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare